REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Clinical trials for REFRACTORY WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Oral drug combo tested for rare blood cancer
Disease control TerminatedThis study tested a combination of two oral drugs, ibrutinib and ixazomib, for patients with Waldenström macroglobulinemia, a rare type of blood cancer. The goal was to see if taking these two drugs together was safe and effective for patients whose cancer was newly diagnosed, ha…
Matched conditions: REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New drug tested for Tough-to-Treat blood cancer
Disease control TerminatedThis early-phase study aimed to find the safest and most effective dose of the drug pomalidomide for patients with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or stopped responding to prior treatments. The trial enrolled 15 patients to carefully monitor s…
Matched conditions: REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC